Oncology Letters

Papers
(The H4-Index of Oncology Letters is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
[Corrigendum] Molecular heterogeneity of guanine nucleotide binding‑protein γ subunit 4 in left‑ and right‑sided colon cancer68
Synchronous primary colorectal mucinous adenocarcinoma and pancreatic ductal adenocarcinoma: A case report51
Metanephric adenoma in children: A case report and literature review51
Six autoantibodies as potential differential biomarkers of hepatocellular carcinoma vs. liver cirrhosis and chronic hepatitis: A prospective multi‑institutional study48
Benefits of adjuvant treatment with the Pingxiao capsule in patients with early breast cancer: A single‑center retrospective cohort study45
Immunoexpression of p62/SQSTM1/Sequestosome‑1 in human primary and recurrent IDH1/2 wild‑type glioblastoma: A pilot study43
Long‑term progression‑free survival in HR+/HER2+ advanced breast cancer with combination therapy with a CDK4/6 inhibitor and first‑line maintenance therapy: A case report40
Proteomics analysis reveals elevated RAB21 in serum‑derived extracellular vesicles from patients with follicular thyroid carcinoma38
Primary gingival diffuse large B‑cell lymphoma with muscle invasion: A case report36
Metastatic squamous cell carcinoma in the residual spleen diagnosed with emergency ultrasonography: A case report36
Imaging assessment of tumor densities and sizes following pazopanib treatment for central nervous system solitary fibrous tumors with multiple extracranial metastases: A case series33
Immune checkpoint inhibitors with or without radiotherapy in metastatic non‑small cell lung cancer: A meta‑analysis and literature review33
Low expression of MYCN promotes cisplatin resistance by suppressing cisplatin‑induced apoptosis in epithelial ovarian cancer32
Prognostic value of circWWC3 as a novel survival‑related biomarker for clear cell renal cell carcinoma32
Comparative efficacy and safety of first‑line PD‑1/PD‑L1 inhibitors in immunotherapy for non‑small cell lung cancer:  A network meta‑analysis31
Upregulation of long non‑coding RNA LINC00460 in EGFR‑mutant lung cancer indicates a poor prognosis in patients treated with osimertinib31
Primary osteosarcoma of the kidney: A case report30
[Retracted] Treatment with a selenium‑platinum compound induced T‑cell acute lymphoblastic leukemia/lymphoma cells apoptosis through the mitochondrial signaling pathway30
CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated30
Comprehensive analysis reveals the value of the expression of chromobox family members for bladder urothelial carcinoma prognosis29
Novel therapeutic strategies for non‑small cell lung cancer: Combination therapies with immune checkpoint inhibitors (Review)28
Prediction and verification of the prognostic biomarker SLC2A2 and its association with immune infiltration in gastric cancer28
Upregulated miR‑378a‑3p expression suppresses energy metabolism and promotes apoptosis by targeting a GLUT‑1/ALDOA/PKM2 axis in esophageal carcinoma26
Novel predictive nomograms based on aspartate aminotransferase‑to‑platelet ratio index for hepatocellular carcinoma with post‑operative adjuvant transarterial chemoembolization26
Correlations between serum lipid and Ki‑67 levels in different breast cancer molecular subcategories25
Cancer marker TNFRSF1A: From single‑cell heterogeneity of renal cell carcinoma to functional validation25
Prognostic value of moderate or massive ascites in patients with advanced gastric cancer25
Evaluation of the therapeutic effects and tolerability of modified lenvatinib administration methods for unresectable hepatocellular carcinoma: A preliminary study25
0.24786496162415